HLA-C and neoplasm: CART involves lymphocytes entirely engineered to recognize any cell surface structure, independently of the MHC (major histocompatibility complex) presentation, leading to stronger T cell activation, a more robust anti-tumor response in vivo, and the eradication of tumor cells [7].